Publication: Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac
Date
Authors
Yalçın, Murat
Coşkun, Melis Debreli
Authors
Sudha, Thangirala
Bharali, Dhruba J.
Darwish, Noureldien H. E.
Keating, Kelly A.
Lin, Hung-Yun
Davis, Paul J.
Mousa, Shaker A. Shaker A.
Advisor
Language
Type
Publisher:
Dove Medical
Journal Title
Journal ISSN
Volume Title
Abstract
The tetraiodothyroacetic acid (tetrac) component of nano-diamino-tetrac (NDAT) is chemically bonded via a linker to a poly(lactic-co-glycolic acid) nanoparticle that can encapsulate anticancer drugs. Tetrac targets the plasma membrane of cancer cells at a receptor on the extracellular domain of integrin alpha v beta 3. In this study, we evaluate the efficiency of NDAT delivery of paclitaxel and doxorubicin to, respectively, pancreatic and breast cancer orthotopic nude mouse xenografts. Intra-tumoral drug concentrations were 5-fold (paclitaxel; P < 0.001) and 2.3-fold (doxorubicin; P < 0.01) higher than with conventional systemic drug administration. Tumor volume reductions reflected enhanced xenograft drug uptake. Cell viability was estimated by bioluminescent signaling in pancreatic tumors and confirmed an increased paclitaxel effect with drug delivery by NDAT. NDAT delivery of chemotherapy increases drug delivery to cancers and increases drug efficacy.
Description
NanoPharmaceuticals LLC (Rensselaer, NY, USA)
Source:
Keywords:
Keywords
Science & technology - other topics, Pharmacology & pharmacy, Doxorubicin, Integrin, Nanoparticle, Nanotetrac, NDAT, Paclitaxel, Tetraiodothyroacetic acid, Xenografts, Activated protein-kinase, Tetraiodothyroacetic acid, Thyroid-hormone, In-vitro, Co-delivery, Cells, Nanomedicine, Receptor, Growth, Cisplatin
Citation
Sudha, T. vd. (2017). ''Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac''. International Journal of Nanomedicine, 12, 1305-1315.